Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Talk to the deal team
PartnerLondon, United Kingdom
Bigtincan (ASX:BTH) has raised capital to fund the acquisition of Brainshark Inc.
Bigtincan Holdings Limited (ASX:BTH) has raised US$98.6 via a placement and underwritten accelerated non-renounceable entitlement offer.Learn more
Alice Queen (ASX:AQX) has raised funds via an institutional placement
Alice Queen Limited (ASX:AQX) has completed a fundraising. The funds will be used to complete the Horn Island Scoping Study, accelerate exploration activities at Horn Island and support working capital. The placement was significantly oversubscribed and strongly supported by a major shareholder, as well as several existing shareholders and new institutional and sophisticated investors.Learn more
Poolbeg Pharma has completed an Initial Public Offering on AIM
Poolbeg Pharma Plc has raised funds to develop the company.Learn more